Pharma BD Deal Intelligence
Peer-reviewed analysis identified economic and technological drivers of generic sterile injectable shortages — quality investment disincentives and price…
FTC conditioned approval on divestiture of 11 generic injectables where Mylan and Agila overlapped, confirming substantial market concentration concerns but…
FDA on three sterile injectables sites acquired from Agila: 'These items found at three different sites, together with other deficiencies found by our…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Mylan to acquire Agila Specialties from Strides Arcolab for $1.6B cash + up to $250M contingent ($1.75B total); created leading global injectables platform.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Mylan Inc. / Agila Specialties (Strides Arcolab) (this deal) | 2013 | $1.8B | 45 |
| Mylan Inc. / Theravance Biopharma, Inc. (TD-4208 program) | 2015 | $265M | 61 |
| Mylan Inc. / Bioniche Pharma Holdings Limited | 2010 | $550M | 60 |
| Mylan Inc. / Famy Care Limited (women's healthcare businesses) | 2015 | $800M | 56 |
| Mylan Inc. / Abbott Laboratories (non-U.S. developed-markets specialty and branded generics business) | 2014 | $5.3B | 33 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
← Browse all deals · How we score deals
More: 2013 deals · Mylan Inc. deals · Other deals